These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 24472120

  • 1. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M, Raymond V, Paradis PE.
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
    Knight C, Howard P, Baker CL, Marton JP.
    Value Health; 2010 May; 13(2):209-14. PubMed ID: 19912599
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [Abstract] [Full Text] [Related]

  • 5. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.
    Clin Drug Investig; 2009 Feb; 29(10):655-65. PubMed ID: 19715382
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P, Knight C, Boler A, Baker C.
    Pharmacoeconomics; 2008 Jan; 26(6):497-511. PubMed ID: 18489200
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
    Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K.
    Acta Clin Belg; 2012 Jan; 67(6):416-22. PubMed ID: 23340147
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
    Tosanguan J, Chaiyakunapruk N.
    Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507
    [Abstract] [Full Text] [Related]

  • 14. Re-treatment with varenicline is a cost-effective aid for smoking cessation.
    Kautiainen K, Ekroos H, Puhakka M, Liira H, Laine J, Linden K, Hahl J.
    J Med Econ; 2017 Mar; 20(3):246-252. PubMed ID: 27754739
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
    Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, Lorza-Blasco JJ, Riesco-Miranda JA, Altet-Gomez N, Barrueco M, Oyagüez I, Rejas J, SESEPARAR’s Integrated Tobacco Research Program.
    Int J Chron Obstruct Pulmon Dis; 2015 Mar; 10():2027-36. PubMed ID: 26451100
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.
    Keeney E, Welton NJ, Stevenson M, Dalili MN, López-López JA, Caldwell DM, Phillippo DM, Munafò MR, Thomas KH.
    Value Health; 2021 Jun; 24(6):780-788. PubMed ID: 34119075
    [Abstract] [Full Text] [Related]

  • 19. [Cost-Effectiveness of Pharmacological Smoking Cessation Therapies - A Systematic Literature Review].
    Aumann I, Rozanski K, Damm K, Graf von der Schulenburg JM.
    Gesundheitswesen; 2016 Oct; 78(10):660-671. PubMed ID: 27784123
    [Abstract] [Full Text] [Related]

  • 20. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY, Lim SS, Wallace AL, Vos T.
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.